155 related articles for article (PubMed ID: 32709489)
1. Molecular genomic profiling of adrenocortical cancers in clinical practice.
Darabi S; Braxton DR; Eisenberg BL; Demeure MJ
Surgery; 2021 Jan; 169(1):138-144. PubMed ID: 32709489
[TBL] [Abstract][Full Text] [Related]
2. Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication.
Lippert J; Appenzeller S; Liang R; Sbiera S; Kircher S; Altieri B; Nanda I; Weigand I; Gehrig A; Steinhauer S; Riemens RJM; Rosenwald A; Müller CR; Kroiss M; Rost S; Fassnacht M; Ronchi CL
J Clin Endocrinol Metab; 2018 Dec; 103(12):4511-4523. PubMed ID: 30113656
[TBL] [Abstract][Full Text] [Related]
3. Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies.
Ross JS; Wang K; Rand JV; Gay L; Presta MJ; Sheehan CE; Ali SM; Elvin JA; Labrecque E; Hiemstra C; Buell J; Otto GA; Yelensky R; Lipson D; Morosini D; Chmielecki J; Miller VA; Stephens PJ
J Clin Pathol; 2014 Nov; 67(11):968-73. PubMed ID: 25078331
[TBL] [Abstract][Full Text] [Related]
4. Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma.
Nazha B; Zhuang TZ; Dada HI; Drusbosky LM; Brown JT; Ravindranathan D; Carthon BC; Kucuk O; Goldman J; Master VA; Bilen MA
Oncologist; 2022 Jun; 27(6):462-468. PubMed ID: 35462410
[TBL] [Abstract][Full Text] [Related]
5. Sarcomatoid adrenocortical carcinoma: a comprehensive pathological, immunohistochemical, and targeted next-generation sequencing analysis.
Papathomas TG; Duregon E; Korpershoek E; Restuccia DF; van Marion R; Cappellesso R; Sturm N; Rossi G; Coli A; Zucchini N; Stoop H; Oosterhuis W; Ventura L; Volante M; Fassina A; Dinjens WN; Papotti M; de Krijger RR
Hum Pathol; 2016 Dec; 58():113-122. PubMed ID: 27589897
[TBL] [Abstract][Full Text] [Related]
6. General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study.
Lee H; El Jabbour T; Ainechi S; Gay LM; Elvin JA; Vergilio JA; Suh J; Ramkissoon SH; Ali SM; Schrock A; Fabrizio D; Frampton G; Nazeer T; Miller VA; Stephens PJ; Ross JS
Hum Pathol; 2017 Dec; 70():84-91. PubMed ID: 29079173
[TBL] [Abstract][Full Text] [Related]
7. Identification of Clinical and Biologic Correlates Associated With Outcome in Children With Adrenocortical Tumors Without Germline TP53 Mutations: A St Jude Adrenocortical Tumor Registry and Children's Oncology Group Study.
Pinto EM; Rodriguez-Galindo C; Pounds SB; Wang L; Clay MR; Neale G; Garfinkle EAR; Lam CG; Levy CF; Pappo AS; Zambetti GP; Ribeiro RC
J Clin Oncol; 2017 Dec; 35(35):3956-3963. PubMed ID: 29058986
[TBL] [Abstract][Full Text] [Related]
8. Wnt/beta-catenin and 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors.
Gaujoux S; Tissier F; Groussin L; Libé R; Ragazzon B; Launay P; Audebourg A; Dousset B; Bertagna X; Bertherat J
J Clin Endocrinol Metab; 2008 Oct; 93(10):4135-40. PubMed ID: 18647815
[TBL] [Abstract][Full Text] [Related]
9. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
Fumagalli C; Ranghiero A; Gandini S; Corso F; Taormina S; De Camilli E; Rappa A; Vacirca D; Viale G; Guerini-Rocco E; Barberis M
Breast Cancer Res; 2020 Oct; 22(1):107. PubMed ID: 33059724
[TBL] [Abstract][Full Text] [Related]
10. Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition.
Lyu Q; Lin A; Cao M; Xu A; Luo P; Zhang J
Cancer Control; 2020; 27(1):1073274820976665. PubMed ID: 33356494
[TBL] [Abstract][Full Text] [Related]
11. Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
Lee JW; Kim NKD; Lee SH; Cho HW; Ma Y; Ju HY; Yoo KH; Sung KW; Koo HH; Park WY
PLoS One; 2019; 14(11):e0224227. PubMed ID: 31747416
[TBL] [Abstract][Full Text] [Related]
12. Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy.
Kang H; Pettinga D; Schubert AD; Ladenson PW; Ball DW; Chung JH; Schrock AB; Madison R; Frampton GM; Stephens PJ; Ross JS; Miller VA; Ali SM
Oncologist; 2019 Jun; 24(6):791-797. PubMed ID: 30373905
[TBL] [Abstract][Full Text] [Related]
13. Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing.
Cai H; Jing C; Chang X; Ding D; Han T; Yang J; Lu Z; Hu X; Liu Z; Wang J; Shang L; Wu S; Meng P; Lin L; Zhao J; Nie M; Yin K
J Transl Med; 2019 Jun; 17(1):189. PubMed ID: 31164161
[TBL] [Abstract][Full Text] [Related]
14. Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.
Rubin B; Regazzo D; Redaelli M; Mucignat C; Citton M; Iacobone M; Scaroni C; Betterle C; Mantero F; Fassina A; Pezzani R; Boscaro M
Tumour Biol; 2016 Oct; 37(10):13545-13555. PubMed ID: 27468715
[TBL] [Abstract][Full Text] [Related]
15. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.
Durand J; Lampron A; Mazzuco TL; Chapman A; Bourdeau I
J Clin Endocrinol Metab; 2011 Jul; 96(7):E1206-11. PubMed ID: 21565795
[TBL] [Abstract][Full Text] [Related]
16. Wnt/beta-catenin pathway deregulation in childhood adrenocortical tumors.
Leal LF; Mermejo LM; Ramalho LZ; Martinelli CE; Yunes JA; Seidinger AL; Mastellaro MJ; Cardinalli IA; Brandalise SR; Moreira AC; Tone LG; Scrideli CA; Castro M; Antonini SR
J Clin Endocrinol Metab; 2011 Oct; 96(10):3106-14. PubMed ID: 21849527
[TBL] [Abstract][Full Text] [Related]
17. Metastatic and recurrent adrenocortical cancer is not defined by its genomic landscape.
Fojo T; Huff L; Litman T; Im K; Edgerly M; Del Rivero J; Pittaluga S; Merino M; Bates SE; Dean M
BMC Med Genomics; 2020 Nov; 13(1):165. PubMed ID: 33148256
[TBL] [Abstract][Full Text] [Related]
18. Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers.
Yang L; Ye F; Bao L; Zhou X; Wang Z; Hu P; Ouyang N; Li X; Shi Y; Chen G; Xia P; Chui M; Li W; Jia Y; Liu Y; Liu J; Ye J; Zhang Z; Bu H
Cancer Sci; 2019 Apr; 110(4):1389-1400. PubMed ID: 30776175
[TBL] [Abstract][Full Text] [Related]
19. Investigation on the Genomic Characterization of Uterine Sarcoma for rAd-
Xia Y; Wang L; Ma X; Li X
Hum Gene Ther; 2020 Aug; 31(15-16):881-890. PubMed ID: 32013587
[TBL] [Abstract][Full Text] [Related]
20. Investigation of BRAF and CTNNB1 activating mutations in adrenocortical tumors.
Masi G; Lavezzo E; Iacobone M; Favia G; Palù G; Barzon L
J Endocrinol Invest; 2009 Jul; 32(7):597-600. PubMed ID: 19498322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]